A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

This Phase 1 study is testing a new drug called STX-0712 for people with two specific types of blood cancers: chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) — specifically the type that involves a large proportion of monocytic (immune-related) cancer cells. The study is evaluating the safety and appropriate dose of this experimental therapy. **You may be eligible if...** - You have been diagnosed with CMML that has not responded to or has relapsed after at least 4 cycles of standard treatment - You have relapsed or refractory monocytic or monocytic-predominant AML with a low white blood cell count - You are in reasonable health (ECOG performance status 2 or below) with a life expectancy of at least 2 months - You have adequate organ function **You may NOT be eligible if...** - You have active uncontrolled infection or other serious medical conditions - You are unwilling to use contraception if you are of childbearing potential - You do not have the specific CMML or monocytic AML diagnosis required for this trial Talk to your doctor to see if this trial is right for you.